Parithera SA is developing an advanced liquid biopsy platform for real-time, single-cell analysis of circulating tumor cells (CTCs). Their system consists of two main components: ExTrace, an automated microfluidic device that isolates and barcodes CTCs from patient blood samples with high purity (~50%), and ExPlore, an AI-powered analytics suite that identifies biomarkers linked to treatment resistance and drug targets—especially for antibody-drug conjugates (ADCs) and other precision therapies.